ACIU: AC Immune SA

ACIU新闻

• 14:29 INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
• 13:55 AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
• 13:30 PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
• 15:21 Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
• 14:46 Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
• 14:36 Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
• 15:16 UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
• 13:42 Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
• 12:55 Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
• 17:34 NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
• 16:47 uniQure Plunges on Additional Data From Huntington's Disease Study
• 13:22 IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
• 13:11 Here's Why You Should Add URGN Stock to Your Portfolio Now
• 10:43 Best Momentum Stock to Buy for September 30th
• 15:37 AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
• 14:13 KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
• 14:12 Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
• 13:06 Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
• 11:50 Teva's Branded Drugs Take Center Stage in Its Growth Strategy
• 15:04 FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
• 14:45 MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
• 14:03 LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
• 15:02 ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
• 14:28 LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D